comparemela.com

Latest Breaking News On - Rapid mood screener - Page 1 : comparemela.com

Screening for Bipolar: Have You Ever Been Unusually Happy for More than a Week?

In a recent article published in the journal Current Medical Research and Opinion, researchers funded by AbbVie (a pharmaceutical company that sells several medications for depression and bipolar disorder) stated that they had developed a six-question “Rapid Screening Tool” for diagnosing bipolar I. This screening tool is now being promoted in outlets such as Yet, as even a quick look at the research paper reveals, this questionnaire wasn’t even tested as a screening tool, and it relies on questions that mistake adverse reactions to antidepressants and other psychiatric drugs as symptoms of bipolar disorder. But this publication also suggests a larger subject: Is there any evidence for “screening” for psychiatric disorders? And what are the potential harms?

Braxia Scientific Corp is making a scientific case for psychedelic medicine

Pioneering the use of psychedelics to treat mental health and addiction disorders Strong portfolio of research into psychedelics complements ongoing clinical trials What Braxia Scientific does: Braxia Scientific Corp (CSE:BRAX), formerly Champignon Brands Inc (CSE:SHRM) (OTCMKTS:SHRMF) is quickly emerging as a leader in the burgeoning field of psychedelic medicine. The company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders. As one of the first psychedelic companies to go public, the firm’s network of ketamine clinics complements its sharp focus on research and development.

Why Companies Are Betting Big On Psychedelic Drugs To Treat Mental Health Epidemic

Why Companies Are Betting Big On Psychedelic Drugs To Treat Mental Health Epidemic - Financialnewsmedia.com News Commentary Share this article Share this article PALM BEACH, Fla., April 28, 2021 /PRNewswire/  Psychedelic medicine is having a moment. Once dismissed as a party drug for its hallucinogenic effects, ketamine is emerging as a novel alternative treatment for depression. For most, psychedelic drugs conjure up images of the 1960 s, hippies tripping out on LSD or magic mushrooms. However, early studies are finding that psilocybin – the active agent in magic mushrooms – could treat addiction, depression, anxiety and mental health conditions like post-traumatic stress disorder (PTSD). Similarly, cancer patients with painful anxiety over their illness have found more peaceful acceptance after participating in a study that involved intensive therapy and being given a drug that was once a symbol of the 60 s counterculture.  Last year, the US Food and Drug Administrati

AMC Entertainment Holdings (AMC), Canopy Growth Corp (CGC), Clarmin Explorations (CLXPF), COMP SERVICES (CMPS), CURALEAF HLDGS INC by Curaleaf Hldgs Inc (CURLF), FIELD TRIP HEALTH LTD by Field Trip Health Ltd (FTRPF), Gamestop Corp (GME), GW Pharma (GWPH), GW PHARMACEUTICAL (GWPRF), Jazz Pharmaceuticals (JAZZ), Johnson & Johnson (JNJ), NUMINUS WELLNESS INC by NUMINUS WELLNESS INC (LKYSD), MIND MEDICINE MINDMED by MIND MEDICINE MINDMED INC (MMEDF), MYDECINE INNOV GRP by MYDECINE INNOVATIONS GROUP INC (MYCOF), Red White & Bloom Brands (RWBYF) - Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

The Nascent Psychedelic Industry is Booming as Several Companies Have Gone Public and More are Expected to Follow This Route in 2021 to Attract More Capital From Institutional and Retail Investors Competition among the dozens of biopharmaceutical companies is fierce. Many are seeking more capital to conduct expensive and lengthy drug trials and develop intellectual property to synthesize the molecules to help treat various mental disorders. The companies that can bring their Psychedelic drugs to the market first will emerge from the pack and could likely hit a home run. “Within the next six to 12 months, we will see an arms race in the psychedelic space as companies try to innovate and get their drugs to trials and to the market,” says Jason Spatafora, co-founder of MarijuanaStocks.com and head trader at TrueTradingGroup.com. ATAI Life Sciences, a Berlin-based biotech company that is researching both Psychedelic and nonpsychedelic compounds, is expected to go public in 2021

NA Proactive news snapshot: PlantX Life Inc, 1933 Industries Inc, Dyadic International, Inc, Klondike Gold Corp, CleanSpark Inc, IEC Electronics Corp, MGX Minerals Inc, Victory Resources Corporation, Real Luck Group Ltd, Namaste Technologies Inc, Fireweed

NA Proactive news snapshot: PlantX Life Inc, 1933 Industries Inc, Dyadic International, Inc, Klondike Gold Corp, CleanSpark Inc, IEC Electronics Corp, MGX Minerals Inc, Victory Resources Corporation, Real Luck Group Ltd, Namaste Technologies Inc, Fireweed
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.